BioSpace News Archive

Achilles Therapeutics plc (NASDAQ: ACHL), today announced that the first patient has been dosed with personalized clonal neoantigen-reactive T cells, or cNeT, manufactured with the Company’s higher-dose VELOS™ Process 2 in the ongoing Phase I/IIa CHIRON clinical trial for the treatment of advanced non-small cell lung cancer (NSCLC).

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced its financial results for the first quarter ended March 31, 2022 and provided an update on key strategic initiatives.

Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the quarter ended March 31, 2022.

Alkermes plc (Nasdaq: ALKS) today announced the acceptance of four abstracts related to nemvaleukin alfa (nemvaleukin) at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago and virtually.

Viatris Inc. (NASDAQ: VTRS), today reported strong results for the first quarter of 2022.

Marengo Therapeutics, Inc. today announced the appointment of Ke Liu, M.D., Ph.D., as Chief Development Officer, as well as Bruce Chabner, M.D., as Senior Strategic Advisor.

BaroPace, Inc. announces the appointment of Michael Coyle to BaroPace’s Board of Directors.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has completed the divestiture of Sunosi ® (solriamfetol) in the U.S. to Axsome Therapeutics, Inc. (Nasdaq: AXSM).

LENSAR, Inc. today announced financial results for the quarter ended March 31, 2022 and provided an update on operational initiatives.

Exicure, Inc. today announced a poster presentation at TIDES USA 2022, May 9-12, 2022.